This mechanism had direct clinical implications: for instance, tamoxifen treatment in breast cancer patients was shown to downregulate glycolysis and GLUT‐1 expression,44 whereas high expression of GLUT‐1 was linked to poor prognosis in patients with oral squamous cell carcinomas.33 Here, SLC2A1 is linked to breast carcinoma.